ELEKTA AB/ADR (OTCMKTS:EKTAY) – Analysts at Jefferies Financial Group issued their FY2023 earnings per share estimates for shares of ELEKTA AB/ADR in a research note issued to investors on Tuesday, December 4th. Jefferies Financial Group analyst K. Lee expects that the company will post earnings per share of $0.61 for the year.
Several other brokerages have also recently issued reports on EKTAY. UBS Group raised shares of ELEKTA AB/ADR from a “neutral” rating to a “buy” rating in a research note on Wednesday, November 28th. Zacks Investment Research cut shares of ELEKTA AB/ADR from a “buy” rating to a “hold” rating in a research note on Tuesday, August 14th.
About ELEKTA AB/ADR
Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.
Further Reading: The Discount Rate – What You Need to Know
Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.